about
Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataGuideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant womenZika Virus —10 Public Health Achievements in 2016 and Future PrioritiesA Tale of Many Cities: A Contemporary Historical Study of the Implementation of School Closures during the 2009 pA(H1N1) Influenza Pandemic.Public health emergency preparedness: lessons learned about monitoring of interventions from the National Association of County and City Health Official's survey of nonpharmaceutical interventions for pandemic H1N1.Public response to the 2009 influenza A H1N1 pandemic: a polling study in five countries.Selecting nonpharmaceutical strategies to minimize influenza spread: the 2009 influenza A (H1N1) pandemic and beyond.A UMLS-based spell checker for natural language processing in vaccine safetyAcute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.The Brighton Collaboration: enhancing comparability of vaccine safety data.Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Facial nerve palsy including Bell's palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data.Fatigue: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Rash including mucosal involvement: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition & guidelines of data collection, analysis, and presentation of immunization safety data.Robust take following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data.Generalized vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.Inadvertent inoculation as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data.Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data.Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data.A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies.Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems.Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.Creating a vaccine adverse event ontology for public health.Developments in the screening for Chlamydia trachomatis: a review.Concept negation in free text components of vaccine safety reports.Fever after immunization: current concepts and improved future scientific understanding.Assessment of public health events through International Health Regulations, United States, 2007-2011.Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization.Sexually transmitted disease services at US colleges and universities.Travel and Border Health Measures to Prevent the International Spread of Ebola.
P50
Q22251433-DD0769F8-6594-435D-9002-1BEB1DABB578Q26250281-D2B4BFDF-AB5D-48A9-AA12-79B9AB2EB6C2Q28114568-8D435BDC-9FBA-4E9F-98BE-AC9DB907BD24Q30196539-E1065E0D-D627-4DB2-91DE-6A7CB8EBF7BAQ30223850-5350F18B-FD61-4ECD-B378-679353F5A5B1Q30421998-92A2474C-870D-4A05-B54F-734A743F149EQ30423047-890A7543-A7EF-4F30-B144-48D0B733E5B3Q30479034-B6DDA6D3-A32D-4929-A409-20B675D6203DQ30540815-59F17C6E-10FA-4E15-93B9-9E71B1428466Q30804369-5E9E4868-F0F3-497C-BBC4-AECCD8E1F173Q30890095-8B96F7BB-3766-4472-8A13-136A8F147354Q30890134-CFE3234E-EE08-4409-8129-150D375B7301Q31103326-F154FDF2-7666-4FBC-8601-ACF6E0B40C5EQ31107779-A231BDE2-6EA4-4C11-9AF1-0BE5C5AED4E4Q31107914-D781808D-089E-4E82-8BD1-8FA580244466Q31108130-ACDD171D-2ED6-4493-90CB-5DB2AD0810D3Q31113938-FBD200EA-AA1F-45C7-83DE-3D063D1D170FQ31114155-BBB06BA8-1B1D-4816-8294-8F0F338D42AAQ31114158-5E8AD876-A470-43EB-AECF-13703C394194Q31114161-E16151D2-76BC-4114-9817-2B8DA6998A3AQ31114321-57F2B1D1-FE66-451B-AD7C-7F8B1216C1C2Q31114324-59BD134A-4830-4DD2-9CA2-029B29A312FCQ31114573-B0FCA67E-86D3-4EFB-85BD-14FFF66DEEC2Q31114574-CC84DCBE-ED39-4529-8972-4F7B21639522Q31114967-2B214AF3-BC40-49E5-860F-2D74D07EFBEEQ31115845-AFCF077F-5A6E-4CFA-BB7B-4E71F4B2DFA8Q33379317-BF8F6854-89AD-46CE-9412-4DD0CEC532F8Q33389704-556BD0CB-5E4F-4340-AA3A-F9F3C5ACD2BAQ33390588-7591CDCE-092C-468B-BFFB-5A7D20CB7E1EQ34258885-10E1C61A-1769-40BD-B2CB-7048D4523663Q34556876-AAC7C023-A789-4A45-922B-3C8E5D0FC768Q34588067-84F7B938-64BD-4FE2-B489-299C4F3A49F0Q35018308-20AAF08E-B2A3-49E2-929C-698F7202E926Q35627542-D4D59302-A23E-48DD-9293-9B6614D81A06Q35727247-A7DB363A-52BF-4346-9910-928A02582C5FQ35861311-A2EFA740-7170-42E1-83C2-8A27170A5F8CQ36037850-C5E98A87-8CC7-49D2-9220-71CDA46C5828Q37274805-564335EF-FC98-4C76-8D13-536A8811FE78Q37865118-275D6503-7E01-42FB-A9D8-16128F87BAA4Q38844096-B8EFC3B6-26FF-451A-BE9E-5F572E4D4471
P50
description
physician epidemiologist
@en
name
Katrin Susanne Kohl
@ast
Katrin Susanne Kohl
@en
Katrin Susanne Kohl
@nl
type
label
Katrin Susanne Kohl
@ast
Katrin Susanne Kohl
@en
Katrin Susanne Kohl
@nl
prefLabel
Katrin Susanne Kohl
@ast
Katrin Susanne Kohl
@en
Katrin Susanne Kohl
@nl
P214
P227
P106
P19
P21
P214
P227
P31
P569
1964-01-01T00:00:00Z
P570
2018-05-20T00:00:00Z